Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669168 | PMC |
| http://dx.doi.org/10.1371/journal.pntd.0004071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finishing the task of eliminating neglected tropical diseases (NTDs) in WHO South-East Asia Region: promises kept, challenges, and the way forward.
Lancet Reg Health Southeast Asia
November 2023
Department of Communicable Diseases, World Health Organization Regional Office for South-East Asia, Delhi, India.
Article Synopsis
- The World Health Organization (WHO) has prioritized 20 Neglected Tropical Diseases (NTDs), with 15 located in the South-East Asia Region, affecting all 11 countries there.
- The region accounts for 54% of the global NTD burden, prompting a focus on eliminating diseases like lymphatic filariasis, kala-azar, yaws, trachoma, and leprosy since 2014.
- Seven countries have successfully eliminated at least one NTD since 2016, and the next decade aims to enhance elimination efforts while applying lessons learned to tackle other NTDs.
The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.
Parasit Vectors
October 2023
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), World Health Organization, Geneva, Switzerland.
Article Synopsis
- The World Health Organization (WHO) laid out its objectives for controlling and eliminating neglected tropical diseases (NTDs) in a 2021-2030 roadmap, emphasizing the need for new treatment options and research.
- A review of current anti-infective drug developments reveals that the existing pipeline cannot meet all treatment needs for NTDs, and WHO allows for off-label drug use based on safety and efficacy.
- The article summarizes the lack of clinical research over the past decade on oral small-molecule drugs for numerous NTDs that are neither approved by regulatory authorities nor included in WHO strategies, identifying specific diseases and drugs that have not been thoroughly evaluated.
Assessing seroprevalence and associated risk factors for multiple infectious diseases in Sabah, Malaysia using serological multiplex bead assays.
Front Public Health
November 2022
Department of Disease Control, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Background: Infectious diseases continue to burden populations in Malaysia, especially among rural communities where resources are limited and access to health care is difficult. Current epidemiological trends of several neglected tropical diseases in these populations are at present absent due to the lack of habitual and efficient surveillance. To date, various studies have explored the utility of serological multiplex beads to monitor numerous diseases simultaneously.
View Article and Find Full Text PDFSecondary Effects from Mass Azithromycin Administration: A Systematic Review and Meta-analysis.
Am J Trop Med Hyg
October 2022
Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children of the Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
The effects of azithromycin mass drug administration (MDA) on trachoma and yaws have been addressed. However, the secondary effects of azithromycin MDA remain unclear. This study aimed to explore the secondary effects of azithromycin MDA.
View Article and Find Full Text PDFA simple, high-throughput and validated LC-MS/MS method for the determination of azithromycin in human plasma and its application to a clinical pharmacokinetic study.
Biomed Chromatogr
October 2022
Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
A sensitive, specific and rapid liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was developed and validated to quantify azithromycin concentrations in human plasma. Azithromycin (AZI) is the most common outpatient prescribed antibiotic in the US and clinical studies have demonstrated the efficacy and safety of AZI in many bacterial infections. To support a clinical study, we developed a high-throughput LC-MS/MS method to process up to 250 samples per day to quantify AZI in human plasma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!